作者
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel, John GF Cleland, Andrew JS Coats, Maria G Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn SP Lam, Alexander R Lyon, John JV McMurray, Alex Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe Rosano, Frank Ruschitzka, Anne Kathrine Skibelund, Rudolf A de Boer, P Christian Schulze, Magdy Abdelhamid, Victor Aboyans, Stamatis Adamopoulos, Stefan D Anker, Elena Arbelo, Riccardo Asteggiano, Johann Bauersachs, Antoni Bayes-Genis, Michael A Borger, Werner Budts, Maja Cikes, Kevin Damman, Victoria Delgado, Paul Dendale, Polychronis Dilaveris, Heinz Drexel, Justin Ezekowitz, Volkmar Falk, Laurent Fauchier, Gerasimos Filippatos, Alan Fraser, Norbert Frey, Chris P Gale, Finn Gustafsson, Julie Harris, Bernard Iung, Stefan Janssens, Mariell Jessup, Aleksandra Konradi, Dipak Kotecha, Ekaterini Lambrinou, Patrizio Lancellotti, Ulf Landmesser, Christophe Leclercq, Basil S Lewis, Francisco Leyva, Aleš Linhart, Maja-Lisa Løchen, Lars H Lund, Donna Mancini, Josep Masip, Davor Milicic, Christian Mueller, Holger Nef, Jens-Cosedis Nielsen, Lis Neubeck, Michel Noutsias, Steffen E Petersen, Anna Sonia Petronio, Piotr Ponikowski, Eva Prescott, Amina Rakisheva, Dimitrios J Richter, Evgeny Schlyakhto, Petar Seferovic, Michele Senni, Marta Sitges, Miguel Sousa-Uva, Carlo G Tocchetti, Rhian M Touyz, Carsten Tschoepe, Johannes Waltenberger, Alexandre Mebazaa, Massimo Francesco Piepoli, Anne Kathrine Skibelund
发表日期
2021/8/27
期刊
European Heart Journal
简介
The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence. Fortunately, we now have a wealth of clinical trials to help us select the best management to improve the outcomes for people with HF; for many, it is now both preventable and treatable. This guideline provides practical, evidence-based recommendations. We have revised the format of the previous 2016 ESC HF Guidelines 1 to make each phenotype of HF stand-alone in terms of its diagnosis and management. The therapy recommendations mention the treatment effect supported by the class and level of evidence and are presented in tables. For HF with reduced ejection fraction (HFrEF), the tabular recommendations focus on mortality and morbidity outcomes. Where there are symptomatic benefits, these are highlighted in the text and/or in the web appendices. Detailed …
引用总数